CN Patent

CN112062695B — 一种前列腺特异性膜抗原靶向抑制剂及应用和探针

Assigned to Yunnan Baiyao Group Co Ltd · Expires 2021-04-06 · 5y expired

What this patent protects

本发明属于核医学领域，涉及一种前列腺特异性膜抗原靶向抑制剂及应用和探针。该抑制剂为具有式I所示结构化合物中的至少一种。本发明提供的靶向PSMA的探针在肿瘤内的摄取是 68 Ga‑PSMA617(现行金标准之一)的1.45倍，肿瘤/肌肉和肿瘤/肾脏的比值与 68 Ga‑PSMA617相当。可见，该探针是非常具有应用前景的三七素类PSMA靶向分子探针。

USPTO Abstract

本发明属于核医学领域，涉及一种前列腺特异性膜抗原靶向抑制剂及应用和探针。该抑制剂为具有式I所示结构化合物中的至少一种。本发明提供的靶向PSMA的探针在肿瘤内的摄取是 68 Ga‑PSMA617(现行金标准之一)的1.45倍，肿瘤/肌肉和肿瘤/肾脏的比值与 68 Ga‑PSMA617相当。可见，该探针是非常具有应用前景的三七素类PSMA靶向分子探针。

Drugs covered by this patent

Patent Metadata

Patent number
CN112062695B
Jurisdiction
CN
Classification
—
Expires
2021-04-06
Drug substance claim
No
Drug product claim
No
Assignee
Yunnan Baiyao Group Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.